Quarterly report pursuant to Section 13 or 15(d)

Loss Per Common Share

v3.7.0.1
Loss Per Common Share
 9 Months Ended
Mar. 31, 2017
Earnings Per Share [Abstract]  
Earnings Per Share [Text Block]
10.
Loss Per Common Share
 
Basic loss per common share is computed by dividing the net loss allocated to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For purposes of calculating diluted loss per common share, the denominator includes both the weighted-average number of shares of common stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. The following table summarizes the components of the loss per common share calculation (in thousands, except per share amounts):
 
 
 
Three Months ended
 
Nine Months ended
 
 
 
March 31,
 
March 31,
 
 
 
2017
 
2016
 
2017
 
2016
 
Basic and diluted numerator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net loss attributable to iBio, Inc.
 
$
(3,913)
 
$
(3,036)
 
$
(10,203)
 
$
(7,087)
 
Preferred stock dividends
 
 
26
 
 
-
 
 
26
 
 
-
 
Net loss available to iBio, Inc. stockholders
 
$
(3,939)
 
$
(3,036)
 
$
(10,229)
 
$
(7,087)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted denominator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weighted-average common shares outstanding
 
 
89,109
 
 
81,158
 
 
89,109
 
 
78,587
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Per share amount
 
$
(0.04)
 
$
(0.04)
 
$
(0.11)
 
$
(0.09)
 
 
In Fiscal 2017 and Fiscal 2016, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of March 31, 2017, shares issuable which could potentially dilute future earnings included approximately 12.3 million stock options.   As of March 31, 2016, shares issuable which could potentially dilute future earnings included approximately 12.3 million stock options and 30,000 warrants.